Another advanced prostate cancer treatment milestone has been reached at Uniting Care Medical Imaging’s (UCMI) Wesley Medical Imaging clinic.
In August 2017, UCMI completed the first Queensland Lutetium 177 PSMA Therapy for advanced prostate cancer.
On the 13 September 2018, UCMI administered the 100th treatment to hopeful men in their quest to fight the disease. This is an exciting milestone for UCMI and also for the Queensland community who has access to this treatment.
About Lutetium-177 PSMA
Lutetium-177 PSMA is a new type of theranostics treatment for advanced prostate cancer. The treatment works by delivering an injection of therapeutic radiation directly to the prostate cancer and its metastases.
This non-invasive prostate cancer treatment aims to reduce the size of the tumour/s and stop them from multiplying and as a result easing the symptoms caused by the tumours. Furthermore in the majority of cases, Lutetium 177 PSMA therapy stabilises or improves disease that has previously been progressive.
About Theranostics Treatments
Lutetium-177 PSMA is part of the broader portfolio of Theranostics treatments. Unitingcare Medical Imaging offers a range of Theranostic treatments for other disease processes.